AppliedVR has received more than $2.9 million in funding to support clinical trials to study virtual reality (VR) platforms as a therapeutic alternative for acute and chronic pain.
➨ The grants will enable AppliedVR to advance two clinical trial programmes with Geisinger and Cleveland Clinic
➨ They will study VR therapeutic platforms RelieVRx and EaseVRx
➨ The company is aiming for FDA approval
The developer of VR therapeutic platforms, based in Los Angeles, was awarded two multi-year grants totaling more than $2.9 million from the National Institute on Drug Abuse (NIDA), which is part of the National Institutes of Health (NIH).
The grants will enable AppliedVR to advance two clinical trial programmes with Geisinger and Cleveland Clinic, studying two of its VR therapeutic platforms, RelieVRx and EaseVRx.
AppliedVR said the NIDA-funded trials will help inform its regulatory pathway with the US Food and Drug Administration (FDA).
“We are grateful to NIDA for its confidence in our vision and ability to execute a novel opioid-sparing treatment option,” commented Dr Beth Darnall, chief science advisor to AppliedVR. “Novel opioid-sparing treatment options are necessary in addressing the opioid epidemic, and we plan to leverage these grants and our existing expertise to address this unmet need in pain management.”
Matthew Stoudt, chief executive officer at AppliedVR, welcomed the funding, saying: “We are honoured to receive these awards from NIDA/NIH, which we believe will not only help forge clinical and regulatory pathways to approval, but more importantly, offer new tools that address the major opioid epidemic.”
“Beyond advancing this novel intervention, this represents an important milestone in advancing therapeutic virtual reality as a new standard of care.”
Watch how AppliedVR helped a musician who had undergone numerous surgeries in the video below:
Image credit: AppliedVR